Influence social and healthcare support on psychiatric adverse events in MDR-TB patient

Influence social and healthcare support on psychiatric adverse events in MDR-TB patient

Introduction: Multidrug resistance tuberculosis (MDR-TB) is a continuing threat because the treatment is rather toxic. One of the causes of poor treatment outcome is due to the adverse events, especially the occurrence of psychiatric adverse events. Methodology: The two cases presented in this p...

Full description

Saved in:

Bibliographic Details
Main Authors:	Reviono Reviono, Harsini Harsini, Jatu Aphridasari, I Gusti Bagus Indro Nugroho, Kusmadewi Eka Damayanti
Format:	Article
Language:	English
Published:	The Journal of Infection in Developing Countries 2018-07-01
Series:	Journal of Infection in Developing Countries
Subjects:	psychiatric adverse events multi-drug resistant tuberculosis patients social support
Online Access:	https://jidc.org/index.php/journal/article/view/10352
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Psychiatric safety associated with hormone replacement therapy for menopausal symptoms: a real-world study of the FDA adverse event reporting system
by: Nan Chen, et al.
Published: (2025-06-01)

Perampanel-associated Psychiatric Problems
by: Anil Kakunje, et al.
Published: (2024-01-01)

Three aspects of acupuncture-related adverse events: Issues around the reporting of acupuncture-related adverse events
by: Tae-Hun Kim, et al.
Published: (2023-09-01)

The Influence of Frailty on Pharmacotherapy Adherence and Adverse Drug Reactions in Older Psychiatric Patients
by: Tuan Anh Phan, et al.
Published: (2025-04-01)

Adverse events associated with gepants: a pharmacovigilance analysis based on the FDA adverse event reporting system
by: Qi Song, et al.
Published: (2025-06-01)

Safety of chemotherapy of MDR/XDR-TB patients in high HIV prevalence settings
by: A. V. Kukurika, et al.
Published: (2022-12-01)

Neuropsychiatric adverse events in people with HIV initiating a new integrase strand transfer inhibitor-based regimen in Italy: findings from the NEURO-INSTI study
by: Nicola Squillace, et al.
Published: (2025-05-01)

Signal mining and risk analysis of olanzapine adverse events in the FAERS database
by: Aiguo Dong, et al.
Published: (2025-07-01)

Descriptive Analysis of Reported Adverse Events Associated with Vitiligo Medications Using FDA Adverse Event Reporting System (FAERS) Databases 2013–2023
by: Saleh F. Alqifari, et al.
Published: (2025-07-01)

Adverse event profile differences between maribavir and valganciclovir: findings from the FDA adverse event reporting system
by: Haolin Teng, et al.
Published: (2025-05-01)

Suicidality Risks Associated with Finasteride, a 5-Alpha Reductase Inhibitor: An Evaluation of Real-World Data from the FDA Adverse Event Reports
by: Hilal A. Thaibah, et al.
Published: (2025-06-01)

Comprehensive analysis of adverse events associated with vortioxetine using the FDA adverse event reporting system
by: Liangxia Li, et al.
Published: (2025-05-01)

Updated insights into adverse events associated with mepolizumab: a disproportionality analysis from the FDA adverse event reporting system database
by: Shan Lin, et al.
Published: (2024-10-01)

Surveillance for adverse events following immunization in Hebei Province, China, 2018-2020
by: Li Sun, et al.
Published: (2024-12-01)

Possible Association Between Concomitant Use of SSRIs with NSAIDs and an Increased Risk of Adverse Events Among People with Depressive Disorders: Data Mining of FDA Adverse Event Reporting System
by: Yi Zhang, et al.
Published: (2025-07-01)

Adverse events in the neonatal intensive care unit identified by triggers
by: Fabiana Bragança Albanese, et al.
Published: (2025-05-01)

Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database
by: Chang-Zhu He, et al.
Published: (2025-03-01)

DARE-SAFE: Denominator-Adjusted Rate Estimates of Substance Adverse Events Frequency Evaluation in Pharmaceuticals and Vaccines
by: Matthew Halma, et al.
Published: (2025-03-01)

Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system
by: Shiyi Wang, et al.
Published: (2025-02-01)

Neuroinflammation in the Pathogenesis of Psychiatric Disorder
by: Eric Herlambang Sutantio, et al.
Published: (2025-05-01)

Real-world study of adverse events associated with triptan use in migraine treatment based on the U.S. Food and Drug Administration (FDA) adverse event reporting system (FAERS) database
by: Wen-Hui Liu, et al.
Published: (2024-11-01)

Analysis of Adverse Events Associated With Dental Local Anaesthetics Using Food and Drug Administration Adverse Event Reporting System Data
by: Ferit Bayram, et al.
Published: (2025-06-01)

Analysis and mining of brodalumab adverse events based on FAERS database
by: Yue Wan, et al.
Published: (2025-05-01)

A disproportionality analysis of FDA adverse event reporting system events for misoprostol
by: Li Yang, et al.
Published: (2025-01-01)

ADVERSE EVENT OF DRUG THERAPY (THE FIRST RESULTS OF THE STUDY ACCORDING TO THE PROFILE OUTPATIENT REGISTER)
by: Yu. V. Lukina, et al.
Published: (2016-06-01)

Pharmacovigilance study of famciclovir in the Food and Drug administration adverse event reporting system database
by: Runan Fang, et al.
Published: (2024-11-01)

Adverse events associated with amlodipine: a pharmacovigilance study using the FDA adverse event reporting system
by: Jiazhen Jiang, et al.
Published: (2025-05-01)

PSA LEVEL AND ADVERSE EVENTS IN SIXTH AND TENTH SERIES DOCETAXEL CHEMOTHERAPY IN CASTRATE-RESISTANT PROSTATE CANCER (CRPC) PATIENTS
by: Kurnia Penta Seputra, et al.
Published: (2025-01-01)

Safety assessment of laronidase: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)
by: Zhuomiao Lin, et al.
Published: (2025-08-01)

Neurological adverse events associated with antidepressants: a comprehensive 22-year analysis of the FDA adverse event reporting system
by: Qian Yu, et al.
Published: (2025-08-01)

Psychometric Assessment of Adverse Childhood Experiences Using the Adverse Childhood Experiences International Questionnaire in Psychiatric Practice: Specifics, Potential Risks, and Result Accuracy
by: D. A. Temirsultanova, et al.
Published: (2024-12-01)

Evaluation of dermatologic adverse events associated with aromatase inhibitors: insights from the FAERS database
by: Yuan-Yuan Wu, et al.
Published: (2025-05-01)

Correction: Adverse events associated with amlodipine: a pharmacovigilance study using the FDA adverse event reporting system
by: Jiazhen Jiang, et al.
Published: (2025-06-01)

Adverse events of modern antifungal drugs during treatment of invasive fungal infections
by: N. V. Dmitrieva, et al.
Published: (2014-07-01)

Factors influencing adverse events following COVID-19 vaccination
by: Paola Villanueva, et al.
Published: (2024-12-01)

Exploring Novel Adverse Events of Nefecon
by: Jingyu Wang, et al.
Published: (2024-09-01)

An infrequent but unpleasant adverse event of Tamsulosin
by: Antonio Villa
Published: (2024-04-01)

Adverse event reporting following immunization of hepatitis B vaccine: A 13-year review
by: Xiaoying Gong, et al.
Published: (2024-12-01)

Neurological adverse events associated with baclofen: a pharmacovigilance study based on FDA adverse event reporting system
by: Yunhan Zhao, et al.
Published: (2025-05-01)

Ophthalmic corticosteroids-related adverse events: the FDA adverse event reporting system (FAERS) database pharmacovigilance study
by: Chengzhi Liu, et al.
Published: (2024-12-01)